A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

This study is testing a new experimental drug called YL-17231 to see if it can safely shrink or stop the growth of solid tumors. It is specifically designed for patients whose cancer has certain genetic changes known as KRAS, HRAS, or NRAS mutations.

This trial is for adults with advanced solid tumors that have stopped responding to standard treatments or where no other options are left. You must have a confirmed genetic mutation and meet specific blood test requirements to ensure your organs are healthy enough for the study.

Participants will receive the experimental drug YL-17231 while doctors closely monitor your health and any side effects. You will undergo regular medical imaging scans and blood tests to see how your body processes the drug and how your tumor responds to the treatment.

The study is currently recruiting patients at locations in Cincinnati, Ohio; Houston, Texas; and Salt Lake City, Utah. If you are interested, your medical team can help you contact these centers to discuss if this trial is right for you.